HC Wainwright Equities Analysts Decrease Earnings Estimates for Centogene (NASDAQ:CNTG)

Centogene (NASDAQ:CNTG – Get Rating) – Analysts at HC Wainwright decreased their FY2022 earnings estimates for shares of Centogene in a research note issued on Tuesday, January 17th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($1.66) for the year, down from their prior forecast of ($1.64). HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Centogene’s current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Centogene’s FY2023 earnings at ($1.18) EPS.

Centogene Stock Performance

NASDAQ:CNTG opened at $0.98 on Friday. The company has a current ratio of 2.39, a quick ratio of 2.30 and a debt-to-equity ratio of 1.12. The firm has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $1.24. Centogene has a twelve month low of $0.68 and a twelve month high of $5.18. The company has a market capitalization of $26.54 million, a P/E ratio of -0.41 and a beta of -1.08.

Hedge Funds Weigh In On Centogene

An institutional investor recently raised its position in Centogene stock. Platinum Investment Management Ltd. lifted its position in shares of Centogene (NASDAQ:CNTG – Get Rating) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,377,150 shares of the company’s stock after buying an additional 106,000 shares during the quarter. Platinum Investment Management Ltd. owned approximately 8.78% of Centogene worth $2,662,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.17% of the company’s stock.

Centogene Company Profile

(Get Rating)

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.